Molecular Diagnosis & Therapy

, Volume 18, Issue 1, pp 25–38

Individualized Therapy for Hepatitis C Infection: Focus on the Interleukin-28B Polymorphism in Directing Therapy

Review Article


Hepatitis C virus—a major global cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma—affects millions of people worldwide. Pegylated interferon (Peg-IFN) and ribavirin (RBV) had been the standard treatment for a decade until availability of the protease inhibitors in 2011. However, current antiviral therapy is still IFN-based and is associated with significant side effects and variable treatment response. Thus, various host and viral factors have been evaluated before and during treatment for the prediction of sustained virologic response to antiviral therapy. In 2009, genome-wide association studies found the single-nucleotide polymorphisms, located near the host interleukin-28B (IL28B) gene that encodes IFN-λ3, to be the best pretreatment predictor of virologic response to Peg-IFN and RBV therapy in chronic hepatitis C genotype 1 patients. Additionally, inosine triphosphatase (ITPA) gene variants were found to be associated with RBV-induced hemolytic anemia, which could affect treatment dose for selected patients. IL28B, ITPA, and other treatment predictors allowed for a potential individualized approach to treat hepatitis C. In the era of increased overall virologic response rates and good tolerability of the rapidly developing non-IFN oral direct-acting antiviral therapy regimens, the need for individualized treatment is likely to diminish. Various predictors of response, including IL28B will likely be of reduced importance in the near future.


  1. 1.
    Lavanchy D. The global burden of hepatitis C. Liver Int. 2009;29(Suppl 1):74–81.PubMedGoogle Scholar
  2. 2.
    Global Burden of Hepatitis CWG. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004;44(1):20–9.Google Scholar
  3. 3.
    Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011;17(2):107–15.PubMedGoogle Scholar
  4. 4.
    Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–38.PubMedGoogle Scholar
  5. 5.
    Ueno Y, Sollano JD, Farrell GC. Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J Gastroenterol Hepatol. 2009;24(4):531–6.PubMedGoogle Scholar
  6. 6.
    Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. 2004;40(3):484–90.PubMedGoogle Scholar
  7. 7.
    Maynard M, Pradat P, Berthillon P, et al. Clinical relevance of total HCV core antigen testing for hepatitis C monitoring and for predicting patients’ response to therapy. J Viral Hepat. 2003;10(4):318–23.PubMedGoogle Scholar
  8. 8.
    Pradat P, Maynard M, Buti M, et al. The predictive value of core antigen testing for the management of hepatitis C patients receiving pegylated interferon/ribavirin treatment. J Med Virol. 2004;73(3):392–6.PubMedGoogle Scholar
  9. 9.
    Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med. 1996;334(2):77–81.PubMedGoogle Scholar
  10. 10.
    Kurosaki M, Enomoto N, Murakami T, et al. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology. 1997;25(3):750–3PubMedGoogle Scholar
  11. 11.
    Dill MT, Duong FH, Vogt JE, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology. 2011;140(3):1021–31.PubMedGoogle Scholar
  12. 12.
    Honda M, Sakai A, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 2010;139(2):499–509.PubMedGoogle Scholar
  13. 13.
    Lopez-Rodriguez R, Trapero-Marugan M, Borque MJ, et al. Genetic variants of interferon-stimulated genes and IL-28B as host prognostic factors of response to combination treatment for chronic hepatitis C. Clin Pharmacol Ther. 2011;90(5):712–21.PubMedGoogle Scholar
  14. 14.
    Diago M, Castellano G, Garcia-Samaniego J, et al. Association of pretreatment serum interferon gamma inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C. Gut. 2006;55(3):374–9.PubMedGoogle Scholar
  15. 15.
    Reiberger T, Aberle JH, Kundi M, et al. IP-10 correlates with hepatitis C viral load, hepatic inflammation and fibrosis and predicts hepatitis C virus relapse or non-response in HIV-HCV coinfection. Antivir Ther. 2008;13(8):969–76.PubMedGoogle Scholar
  16. 16.
    Zeremski M, Markatou M, Brown QB, Dorante G, Cunningham-Rundles S, Talal AH. Interferon gamma-inducible protein 10: a predictive marker of successful treatment response in hepatitis C virus/HIV-coinfected patients. J Acquir Immune Defic Syndr. 2007;45(3):262–8.PubMedGoogle Scholar
  17. 17.
    Coban S, Idilman R, Erden E, Tuzun A. Gamma-glutamyltranspeptidase in predicting sustained virological response in individuals with chronic hepatitis C. Hepatogastroenterology. 2011;58(109):1301–6.PubMedGoogle Scholar
  18. 18.
    Villela-Nogueira CA, Perez RM, de Segadas Soares JA, Coelho HS. Gamma-glutamyl transferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin. J Clin Gastroenterol. 2005;39(8):728–30.Google Scholar
  19. 19.
    Cui Q, Zhang YX, Su J, et al. Genetic variation in IL28RA is associated with the outcomes of HCV infection in a high-risk Chinese population. Infect Genet Evol. 2011;11(7):1682–9.PubMedGoogle Scholar
  20. 20.
    Jimenez-Sousa MA, Berenguer J, Rallon N, et al. IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients. J Viral Hepat. 2013;20(5):358–66.PubMedGoogle Scholar
  21. 21.
    Morello J, Cuenca L, Soriano V, et al. Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. J Infect Dis. 2010;202(8):1185–91.PubMedGoogle Scholar
  22. 22.
    Tsubota A, Shimada N, Yoshizawa K, et al. Contribution of ribavirin transporter gene polymorphism to treatment response in peginterferon plus ribavirin therapy for HCV genotype 1b patients. Liver Int. 2012;32(5):826–36.PubMedGoogle Scholar
  23. 23.
    Bitetto D, Fattovich G, Fabris C, et al. Complementary role of vitamin D deficiency and the interleukin-28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C. Hepatology. 2011;53(4):1118–26.PubMedGoogle Scholar
  24. 24.
    Lange CM, Bibert S, Kutalik Z, et al. A genetic validation study reveals a role of vitamin D metabolism in the response to interferon-alfa-based therapy of chronic hepatitis C. PLoS ONE. 2012;7(7):e40159.PubMedCentralPubMedGoogle Scholar
  25. 25.
    Mandorfer M, Reiberger T, Payer BA, et al. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV/HCV coinfected patients. AIDS. 2013;27(2):227–32.Google Scholar
  26. 26.
    Petta S, Camma C, Scazzone C, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology. 2010;51(4):1158–67.PubMedGoogle Scholar
  27. 27.
    Petta S, Ferraro D, Camma C, et al. Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C. Antivir Ther. 2012;17(5):823–31.PubMedGoogle Scholar
  28. 28.
    Rocco A, Compare D, Coccoli P, et al. Vitamin B12 supplementation improves rates of sustained viral response in patients chronically infected with hepatitis C virus. Gut. 2013;62(5):766–73.PubMedGoogle Scholar
  29. 29.
    Rosenberg P, Hagen K. Serum B12 levels predict response to treatment with interferon and ribavirin in patients with chronic HCV infection. J Viral Hepat. 2011;18(2):129–34.PubMedGoogle Scholar
  30. 30.
    Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology. 2011;140(7):1961–9.PubMedCentralPubMedGoogle Scholar
  31. 31.
    Ghany MG, Strader DB, Thomas DL, Seeff LB. American Association for the Study of Liver D. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–74.PubMedGoogle Scholar
  32. 32.
    Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.PubMedGoogle Scholar
  33. 33.
    Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338–45.Google Scholar
  34. 34.
    Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100–4.PubMedGoogle Scholar
  35. 35.
    Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–9.PubMedGoogle Scholar
  36. 36.
    Fukuhara T, Taketomi A, Motomura T, et al. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology. 2010;139(5):1577–85.Google Scholar
  37. 37.
    Charlton MR, Thompson A, Veldt BJ, et al. Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection. Hepatology. 2011;53(1):317–24.PubMedGoogle Scholar
  38. 38.
    Lange CM, Moradpour D, Doehring A, et al. Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection. J Hepatol. 2011;55(2):322–7.PubMedGoogle Scholar
  39. 39.
    Duarte-Rojo A, Veldt BJ, Goldstein DD, et al. The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation. 2012;94(2):197–203.PubMedGoogle Scholar
  40. 40.
    Coto-Llerena M, Perez-Del-Pulgar S, Crespo G, et al. Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation. Am J Transplant. 2011;11(5):1051–7.PubMedGoogle Scholar
  41. 41.
    Aparicio E, Parera M, Franco S, et al. IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS ONE. 2010;5(10):e13771.PubMedCentralPubMedGoogle Scholar
  42. 42.
    Labarga P, Barreiro P, Mira JA, et al. Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV-hepatitis C virus-coinfected patients with prior nonresponse or relapse. Aids. 2011;25(8):1131–3.PubMedGoogle Scholar
  43. 43.
    Rallon NI, Naggie S, Benito JM, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. Aids. 2010;24(8):F23–9.PubMedGoogle Scholar
  44. 44.
    Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801.PubMedCentralPubMedGoogle Scholar
  45. 45.
    Tillmann HL, Thompson AJ, Patel K, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology. 2010;139(5):1586–92.Google Scholar
  46. 46.
    Grebely J, Petoumenos K, Hellard M, et al. Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology. 2010;52(4):1216–24.PubMedCentralPubMedGoogle Scholar
  47. 47.
    Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature. 2010;464(7287):405–8.PubMedGoogle Scholar
  48. 48.
    Eskesen AN, Melum E, Moghaddam A, et al. Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort. Eur J Gastroenterol Hepatol. 2012;24(8):890–6.PubMedGoogle Scholar
  49. 49.
    Kurosaki M, Tanaka Y, Tanaka K, et al. Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin. Antivir Ther. 2011;16(5):685–94.PubMedGoogle Scholar
  50. 50.
    Miyamura T, Kanda T, Nakamoto S, et al. Roles of ITPA and IL28B genotypes in chronic hepatitis C patients treated with peginterferon plus ribavirin. Viruses. 2012;4(8):1264–78.PubMedCentralPubMedGoogle Scholar
  51. 51.
    Naggie S, Rallon NI, Benito JM, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with all HCV genotypes. J Infect Dis. 2012;205(3):376–83.PubMedGoogle Scholar
  52. 52.
    Sakamoto N, Tanaka Y, Nakagawa M, et al. ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol Res. 2010;40(11):1063–71.PubMedGoogle Scholar
  53. 53.
    Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011;54(4):1433–44.PubMedCentralPubMedGoogle Scholar
  54. 54.
    Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013;381(9883):2100–7.Google Scholar
  55. 55.
    Muir AJ, Bornstein JD, Killenberg PG. Atlantic Coast Hepatitis Treatment G. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350(22):2265–71.PubMedGoogle Scholar
  56. 56.
    Chayama K, Hayes CN, Abe H, et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis. 2011;204(1):84–93.PubMedGoogle Scholar
  57. 57.
    Hayes CN, Kobayashi M, Akuta N, et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut. 2011;60(2):261–7.PubMedGoogle Scholar
  58. 58.
    Hiraga N, Abe H, Imamura M, et al. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus. Hepatology. 2011;54(3):764–71.PubMedGoogle Scholar
  59. 59.
    Kurosaki M, Tanaka Y, Nishida N, et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol. 2011;54(3):439–48.PubMedGoogle Scholar
  60. 60.
    Lagging M, Askarieh G, Negro F, et al. Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms. PLoS ONE. 2011;6(2):e17232.PubMedCentralPubMedGoogle Scholar
  61. 61.
    Lin CY, Chen JY, Lin TN, et al. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS ONE. 2011;6(3):e18322.PubMedCentralPubMedGoogle Scholar
  62. 62.
    Lindh M, Lagging M, Arnholm B, et al. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1. J Viral Hepat. 2011;18(7):e325–31.PubMedGoogle Scholar
  63. 63.
    Moghaddam A, Melum E, Reinton N, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology. 2011;53(3):746–54.PubMedGoogle Scholar
  64. 64.
    Sinn DH, Kim YJ, Lee ST, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients. J Gastroenterol Hepatol. 2011;26(9):1374–9.PubMedGoogle Scholar
  65. 65.
    Stättermayer AF, Stauber R, Hofer H, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9(4):344–50e.2.Google Scholar
  66. 66.
    Bota S, Sporea I, Sirli R, Neghina AM, Popescu A, Strain M. Role of interleukin-28B polymorphism as a predictor of sustained virological response in patients with chronic hepatitis C treated with triple therapy: a systematic review and meta-analysis. Clin Drug Invest. 2013;33(5):325–31.Google Scholar
  67. 67.
    Chen Y, Xu HX, Wang LJ, Liu XX, Mahato RI, Zhao YR. Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-alpha and ribavirin. Aliment Pharmacol Ther. 2012;36(2):91–103.PubMedGoogle Scholar
  68. 68.
    Li S, Hu P, Zhang QQ, et al. Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: a meta-analysis: meta-analysis of IL28B. Hepat Mon. 2011;11(3):163–72.PubMedCentralPubMedGoogle Scholar
  69. 69.
    Jimenez-Sousa MA, Fernandez-Rodriguez A, Guzman-Fulgencio M, Garcia-Alvarez M, Resino S. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med. 2013;11:6.PubMedCentralPubMedGoogle Scholar
  70. 70.
    Fischer J, Bohm S, Scholz M, et al. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology. 2012;55(6):1700–10.PubMedGoogle Scholar
  71. 71.
    Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010;139(1):120–9.e18.Google Scholar
  72. 72.
    Mangia A, Thompson AJ, Santoro R, et al. Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Hepatology. 2011;54(3):772–80.PubMedGoogle Scholar
  73. 73.
    Sarrazin C, Susser S, Doehring A, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol. 2011;54(3):415–21.PubMedGoogle Scholar
  74. 74.
    Mangia A, Thompson AJ, Santoro R, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology. Sep 2010;139(3):821-827.Google Scholar
  75. 75.
    Asselah T, De Muynck S, Broet P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol. 2012;56(3):527–32.PubMedGoogle Scholar
  76. 76.
    Martin MP, Qi Y, Goedert JJ, et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis. 2010;202(11):1749–53.PubMedGoogle Scholar
  77. 77.
    Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology. 2005;41(2):289–98.PubMedGoogle Scholar
  78. 78.
    Terrault NA, Berenguer M. Treating hepatitis C infection in liver transplant recipients. Liver Transplant. 2006;12(8):1192–204.Google Scholar
  79. 79.
    Allam SR, Kruger B, Mehrotra A, Schiano T, Schroppel B, Murphy B. The association of IL28B polymorphism and graft survival in patients with hepatitis C undergoing liver transplantation. PLoS ONE. 2013;8(1):e54854.PubMedCentralPubMedGoogle Scholar
  80. 80.
    Eurich D, Boas-Knoop S, Ruehl M, et al. Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation. Liver Transplant. 2011;17(3):289–98.Google Scholar
  81. 81.
    Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transplant. 2012;18(9):1053–9.Google Scholar
  82. 82.
    Corey KE, Mendez-Navarro J, Gorospe EC, Zheng H, Chung RT. Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis. J Viral Hepat. 2010;17(3):201–7.PubMedCentralPubMedGoogle Scholar
  83. 83.
    Kamal SM, Fouly AE, Kamel RR, et al. Peginterferon alfa-2b therapy in acute hepatitis C: impact of onset of therapy on sustained virologic response. Gastroenterology. 2006;130(3):632–8.PubMedGoogle Scholar
  84. 84.
    Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology. 2006;43(2):250–6.PubMedGoogle Scholar
  85. 85.
    Grebely J, Matthews GV, Dore GJ. Treatment of acute HCV infection. Nat Rev Gastroenterol Hepatol. 2011;8(5):265–74.PubMedGoogle Scholar
  86. 86.
    Habersetzer F, Leboeuf C, Doffoel M, Baumert TF. Boceprevir and personalized medicine in hepatitis C virus infection. Pharmgenomics Pers Med. 2012;5:125–37.PubMedCentralPubMedGoogle Scholar
  87. 87.
    Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–206.PubMedCentralPubMedGoogle Scholar
  88. 88.
    Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 2012;143(3):608–18.e1-5.Google Scholar
  89. 89.
    Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–16.PubMedGoogle Scholar
  90. 90.
    Jacobson IM, Catlett I, Marcellin P, et al. 1369 Telaprevir substantially improved SVR rates across all IL28B genotypes in the advance trial. J Hepatol. 2011;54:S542–3.Google Scholar
  91. 91.
    Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1207–17.PubMedCentralPubMedGoogle Scholar
  92. 92.
    Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364(25):2417–28.PubMedGoogle Scholar
  93. 93.
    Pol S, Aerssens J, Zeuzem S, et al. Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. J Hepatol. 2013;58(5):883–9.PubMedGoogle Scholar
  94. 94.
    Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2010;376(9751):1467–75.PubMedGoogle Scholar
  95. 95.
    Chu TW, Kulkarni R, Gane EJ, et al. Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C. Gastroenterology. 2012;142(4):790–5.PubMedGoogle Scholar
  96. 96.
    Zeuzem S, Soriano V, Asselah T, et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med. 2013;369(7):630–9PubMedGoogle Scholar
  97. 97.
    Marcello T, Grakoui A, Barba-Spaeth G, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006;131(6):1887–98.PubMedGoogle Scholar
  98. 98.
    Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol. 2005;79(6):3851–4.PubMedCentralPubMedGoogle Scholar
  99. 99.
    Thomas E, Gonzalez VD, Li Q, et al. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology. 2012;142(4):978–88.PubMedCentralPubMedGoogle Scholar
  100. 100.
    Marukian S, Andrus L, Sheahan TP, et al. Hepatitis C virus induces interferon-lambda and interferon-stimulated genes in primary liver cultures. Hepatology. 2011;54(6):1913–23.PubMedCentralPubMedGoogle Scholar
  101. 101.
    Dolganiuc A, Kodys K, Marshall C, et al. Type III interferons, IL-28 and IL-29, are increased in chronic HCV infection and induce myeloid dendritic cell-mediated FoxP3 + regulatory T cells. PLoS ONE. 2012;7(10):e44915.PubMedCentralPubMedGoogle Scholar
  102. 102.
    Pagliaccetti NE, Eduardo R, Kleinstein SH, Mu XJ, Bandi P, Robek MD. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem. 2008;283(44):30079–89.PubMedGoogle Scholar
  103. 103.
    Urban TJ, Thompson AJ, Bradrick SS, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology. 2010;52(6):1888–96.PubMedCentralPubMedGoogle Scholar
  104. 104.
    Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T. Antitumor activity of IFN-lambda in murine tumor models. J Immunol. 2006;176(12):7686–94.PubMedGoogle Scholar
  105. 105.
    Numasaki M, Tagawa M, Iwata F, et al. IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol. 2007;178(8):5086–98.PubMedGoogle Scholar
  106. 106.
    Sixtos-Alonso MS, Sanchez-Munoz F, Sanchez-Avila JF, et al. IFN-stimulated gene expression is a useful potential molecular marker of response to antiviral treatment with Peg-IFNalpha 2b and ribavirin in patients with hepatitis C virus genotype 1. Arch Med Res. 2011;42(1):28–33.PubMedGoogle Scholar
  107. 107.
    Su X, Yee LJ, Im K, et al. Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. J Hepatol. 2008;49(2):184–91.PubMedCentralPubMedGoogle Scholar
  108. 108.
    Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45(2):164–71.PubMedCentralPubMedGoogle Scholar
  109. 109.
    Weng Y, Siciliano SJ, Waldburger KE, et al. Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem. 1998;273(29):18288–91.PubMedGoogle Scholar
  110. 110.
    Zeremski M, Petrovic LM, Chiriboga L, et al. Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology. 2008;48(5):1440–50.PubMedCentralPubMedGoogle Scholar
  111. 111.
    Romero AI, Lagging M, Westin J, et al. Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis. 2006;194(7):895–903.PubMedGoogle Scholar
  112. 112.
    Al-Ashgar HI, Khan MQ, Helmy A, et al. Relationship of interferon-gamma-inducible protein-10 kDa with viral response in patients with various heterogeneities of hepatitis C virus genotype-4. Eur J Gastroenterol Hepatol. 2013;25(4):404–10.PubMedGoogle Scholar
  113. 113.
    Askarieh G, Alsio A, Pugnale P, et al. Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology. 2010;51(5):1523–30.PubMedGoogle Scholar
  114. 114.
    Darling JM, Aerssens J, Fanning G, et al. Quantitation of pretreatment serum interferon-gamma-inducible protein-10 improves the predictive value of an IL28B gene polymorphism for hepatitis C treatment response. Hepatology. 2011;53(1):14–22.PubMedCentralPubMedGoogle Scholar
  115. 115.
    Fattovich G, Covolo L, Bibert S, et al. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C. Aliment Pharmacol Ther. 2011;33(10):1162–72.PubMedGoogle Scholar
  116. 116.
    Payer BA, Reiberger T, Aberle J, et al. IL28B and interferon-gamma inducible protein 10 for prediction of rapid virologic response and sustained virologic response in HIV-HCV-coinfected patients. Eur J Clin Invest. 2012;42(6):599–606.PubMedGoogle Scholar
  117. 117.
    Beinhardt S, Aberle JH, Strasser M, et al. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology. 2012; 142(1):78–85.e2.Google Scholar
  118. 118.
    Itou M, Kawaguchi T, Taniguchi E, et al. Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. J Gastroenterol Hepatol. 2008;23(2):244–51.PubMedGoogle Scholar
  119. 119.
    Firneisz G, Lakatos PL, Szalay F. Hungarian viral hepatitis study G. Serum dipeptidyl peptidase IV (DPP IV, CD26) activity in chronic hepatitis C. Scand J Gastroenterol. 2001;36(8):877–80.PubMedGoogle Scholar
  120. 120.
    Lee S, Macquillan GC, Keane NM, et al. Immunological markers predicting outcome in patients with hepatitis C treated with interferon-alpha and ribavirin. Immunol Cell Biol. 2002;80(4):391–7.PubMedGoogle Scholar
  121. 121.
    Casrouge A, Decalf J, Ahloulay M, et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest. 2011;121(1):308–17.PubMedCentralPubMedGoogle Scholar
  122. 122.
    Gorrell MD, Zekry A, McCaughan GW, Lloyd A. The long and the short of interferon-gamma-inducible protein 10 in hepatitis C virus infection. Hepatology. 2011;54(5):1875–9.PubMedGoogle Scholar
  123. 123.
    Patel K, Lucas JE, Thompson JW, et al. High predictive accuracy of an unbiased proteomic profile for sustained virologic response in chronic hepatitis C patients. Hepatology. 2011;53(6):1809–18.PubMedGoogle Scholar
  124. 124.
    Cyr DD, Lucas JE, Thompson JW, et al. Characterization of serum proteins associated with IL28B genotype among patients with chronic hepatitis C. PLoS ONE. 2011;6(7):e21854.PubMedCentralPubMedGoogle Scholar
  125. 125.
    Falleti E, Bitetto D, Fabris C, et al. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C. Hepatology. 2012;56(5):1641–50.PubMedGoogle Scholar
  126. 126.
    Lange CM, Bojunga J, Ramos-Lopez E, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol. 2011;54(5):887–93.PubMedGoogle Scholar
  127. 127.
    Baur K, Mertens JC, Schmitt J, et al. The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients. Antivir Ther. 2012;17(3):541–7.PubMedGoogle Scholar
  128. 128.
    Kitson MT, Dore GJ, George J, et al. Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol. 2013;58(3):467–72.PubMedGoogle Scholar
  129. 129.
    Li D, Lott WB, Martyn J, Haqshenas G, Gowans EJ. Differential effects on the hepatitis C virus (HCV) internal ribosome entry site by vitamin B12 and the HCV core protein. J Virol. 2004;78(21):12075–81.PubMedCentralPubMedGoogle Scholar
  130. 130.
    Lott WB, Takyar SS, Tuppen J, et al. Vitamin B12 and hepatitis C: molecular biology and human pathology. Proc Natl Acad Sci USA. 2001;98(9):4916–21.PubMedGoogle Scholar
  131. 131.
    Takyar SS, Gowans EJ, Lott WB. Vitamin B12 stalls the 80 S ribosomal complex on the hepatitis C internal ribosome entry site. J Mol Biol. 2002;319(1):1–8.PubMedGoogle Scholar
  132. 132.
    Dixit NM, Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci. 2006;63(7–8):832–42.PubMedGoogle Scholar
  133. 133.
    Iikura M, Furihata T, Mizuguchi M, et al. ENT1, a ribavirin transporter, plays a pivotal role in antiviral efficacy of ribavirin in a hepatitis C virus replication cell system. Antimicrob Agents Chemother. 2012;56(3):1407–13.PubMedCentralPubMedGoogle Scholar
  134. 134.
    Thompson AJ, Fellay J, Patel K, et al. Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology. 2010;139(4):1181–9.PubMedCentralPubMedGoogle Scholar
  135. 135.
    Thompson AJ, Santoro R, Piazzolla V, et al. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Hepatology. 2010;53(2):389–95.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Department of MedicineDuke University Medical CenterDurhamUSA
  2. 2.Division of GastroenterologyDuke University Medical CenterDurhamUSA
  3. 3.Duke Clinical Research InstituteDurhamUSA

Personalised recommendations